Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
724studies shown
Showing 126-150 of 724
RecruitingNCT07084831

A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

This study is looking at be the first to take a deep look at cognitive function over a full year of XT treatment for people with Schizophrenia, Psychosis, or Cognitive Impairment. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
Austria, Belgium, Czech Republic, Denmark, Germany, Hungary, Israel, Italy, Netherlands, Spain
Sponsor
European Group for Research In Schizophrenia
Condition
Schizophrenia
RecruitingNCT06470516

The Hi-tACS on Cognitive Function in Patients With Schizophrenia

This study is comparing high-frequency transcranial alternating current stimulation with sham-treatment arm for people with Schizophrenia. Participants receive high-frequency transcranial alternating current stimulation or sham-treatment arm and complete study visits and assessments.

SchizophreniaOtherOver 18 Years
Countries
China
Sponsor
Sir Run Run Shaw Hospital
Condition
Schizophrenia
RecruitingNCT07010614

Brain Stimulation to the Hippocampus in Schizophrenia

This study is looking at whether Intracranial electrodes can help people with Schizophrenia Disorders, Mental Disorder, or psychosis. Participants take part in Intracranial electrodes and complete follow-up assessments.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Stanford University
Condition
Schizophrenia
RecruitingNCT07434479

A Virtual Reality Mindfulness Application for Aggression in Schizophrenia

This study is looking at whether an online mindfulness program can help people with Schizophrenia Disorder, Schizoaffecitve Disorder, or Aggression. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
United States
Sponsor
Manhattan Psychiatric Center
Condition
Schizophrenia
RecruitingNCT04368039

Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis

This study is looking at whether Normobaric Oxygen can help people with Psychosis, Schizophrenia, or First-episode Psychosis. Participants take part in Normobaric Oxygen and complete follow-up assessments.

SchizophreniaOtherFrom 15 Years to 35 Years
Countries
United States
Sponsor
Nicholas Breitborde
Condition
Schizophrenia
RecruitingNCT07196462

Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia

This study is comparing 3 Minute iTBS to the L DLPFC with Precision Brain Stimulation for Cannabis Users with Healthy Controls for people with Cannabis Use, Schizophrenia, Psychosis, or Rtms. Participants receive 3 Minute iTBS to the L DLPFC or Precision Brain Stimulation for Cannabis Users with Healthy Controls and complete study visits and assessments.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Vanderbilt University Medical Center
Condition
Schizophrenia
RecruitingNCT06865937

Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness (R33)

This study is looking at whether Mobile Intervention for Social Recovery in Serious Mental Illness (mSITE) can help people with Schizophenia Disorder or schizoaffective disorder. Participants take part in Mobile Intervention for Social Recovery in Serious Mental Illness (mSITE) and complete follow-up assessments.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of California, San Diego
Condition
Schizophrenia
RecruitingNCT07428460

Accelerated Neuromodulation Therapy for Negative Symptoms of Schizophrenia

This study is looking at whether a digital support tool can help people with Schizophrenia and Predominant Negative Symptoms. Participants take part in the program and complete follow-up questionnaires or assessments.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Canada
Sponsor
Douglas Mental Health University Institute
Condition
Schizophrenia
RecruitingNCT07288567

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

This study is looking at evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 13 Years to 17 Years
Countries
Argentina, Colombia, Japan, Romania, United States
Sponsor
Bristol-Myers Squibb
Condition
Schizophrenia
RecruitingNCT06641297

White Matter Plasticity in Schizophrenia

This study is looking at care and outcomes for people with Schizophrenia Disorders. Taking part may give some people access to Music video game, but direct benefit is not guaranteed.

SchizophreniaOtherFrom 15 Years to 45 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
RecruitingNCT07419321

Social Isolation and Aging in Schizophrenia

This study is looking at be the first to comprehensively examine the health impact of social isolation in SZ for people with Schizophrenia and Related Disorders. Participants are followed over time so researchers can learn from clinical and follow-up information.

SchizophreniaOtherFrom 40 Years to 70 Years
Countries
Netherlands, Spain, United Kingdom, United States
Sponsor
Icahn School of Medicine at Mount Sinai
Condition
Schizophrenia
RecruitingNCT07231497

Cognitive Strategies in Early Psychosis 1

This study is looking at whether a digital support tool can help people with Cognition or Healthy Participants. Participants receive a study treatment and complete follow-up visits and assessments.

SchizophreniaOtherFrom 18 Years to 35 Years
Countries
United States
Sponsor
University of Minnesota
Condition
Schizophrenia
RecruitingNCT07217652

Investigating Mediodorsal Thalamus Representations Underlying Human Cognitive Flexibility

This study is looking at examine how the human thalamus supports flexible thinking and behavior for people with Schizophrenia or Attention Deficit Disorder With Hyperactivity. Some participants may receive Within subject manipulation of working memory, cognitive control, and decision making instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 18 Years to 35 Years
Countries
United States
Sponsor
Kai Hwang
Condition
Schizophrenia
RecruitingNCT06155682

TMS for Inhibition Enhancement in Schizophrenia

This study is comparing repetitive transcranial magnetic stimulation (active) with sham rTMS for people with Schizophrenia. Participants receive repetitive transcranial magnetic stimulation (active) or sham rTMS and complete study visits and assessments.

SchizophreniaOtherFrom 18 Years to 45 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
RecruitingNCT05102929

Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia

This study is looking at care and outcomes for people with Schizophrenia. Some participants may receive active, then sham Intermittent Theta Burst Stimulation (iTBS) over DLPFC instead of the study treatment, and direct benefit is not guaranteed.

SchizophreniaOtherFrom 18 Years to 40 Years
Countries
United States
Sponsor
Fabio Ferrarelli
Condition
Schizophrenia
RecruitingNCT07397975

Speech-based Assessment of Relapse Risk in People With Psychosis

This observational study is following people with psychosis to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Czech Republic, Ireland, Netherlands, Norway, Switzerland, Turkey
Sponsor
Philipp Homan
Condition
Schizophrenia
RecruitingNCT05669742

Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients

This study is comparing Empagliflozin with Group 1 as control group for people with Sodium-glucose Transport Protein Two Inhibitor,Metabolic Deficits Caused by Antipsychotics. Participants receive Empagliflozin or Group 1 as control group and complete study visits and assessments.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Egypt
Sponsor
Tanta University
Condition
Schizophrenia